Business Standard

Multiple triggers likely to help Zydus to continue with its outperformance

New launches in the US, market share gains and steady domestic growth are positives

Multiple triggers likely to help Zydus maintain its outperformance
Premium

Ram Prasad Sahu
Even as most of its large-cap pharmaceutical peers have struggled to stay above water on the returns front, Zydus Lifesciences has been one of the big outperformers within the sector over the past year with a return of over 30 per cent.

The gains have come on the back of multiple triggers such as the scaling up of new product launches in the US market, clearance for its Moraiya (Gujarat) facility and steady performance in the domestic market. Though it has been the top pharma gainer in the 2022-23 financial year (FY23), brokerages continue to maintain their ‘buy’ stance, given

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 23 2023 | 9:20 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com